Company news
Opko Health, Inc. (NASDAQ:OPK) news
Opko Health, Inc. news releases on 6ix. Latest, Sep 8, 2026: OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
Press releases & updates
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 8, 2026
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
August 13, 2026
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
July 27, 2026
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
July 23, 2026
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
June 15, 2026
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
May 12, 2026
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
April 30, 2026
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
April 30, 2026
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
April 28, 2026
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
April 22, 2026
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
April 21, 2026
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
April 7, 2026
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
February 26, 2026
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
February 26, 2026
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
February 12, 2026
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
February 3, 2026
OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
NextPlat Reports Third Quarter 2025 Results
November 12, 2025
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
October 30, 2025
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
October 28, 2025
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
October 28, 2025
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
October 27, 2025
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
October 21, 2025
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
September 15, 2025
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
July 30, 2025
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
July 23, 2025
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
July 7, 2025
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
June 24, 2025
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
June 24, 2025
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
June 8, 2025
OPKO Health to Participate in Two Upcoming Investor Conferences
May 14, 2025
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results
April 29, 2025
OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025
April 16, 2025
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
April 3, 2025
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
March 16, 2025
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
February 26, 2025
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
February 12, 2025
OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 8, 2025
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
January 6, 2025
OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 19, 2024
NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
November 13, 2024
OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results
November 6, 2024
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
October 28, 2024
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
October 6, 2024
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
September 24, 2024
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
September 22, 2024
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
September 15, 2024
OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
August 6, 2024
OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024
July 31, 2024